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Parathyroidhormone(PTH)assayshaveevolvedcontinuouslyforthelast50years.Sincetheﬁrstradioimmunoassaywasdescribed
in1963,severalassaysbasedonimmunologicalidentiﬁcationhavebeenpublished(ﬁrstgenerationassays).Theroutineassaysused
nowadays are immunometric “sandwich-type”. They are based on two diﬀerent monoclonal antibodies, one amino-terminal and
the other carboxyl terminal speciﬁc. These second generation assays are widely available and adapted to most of the automation
platforms. The speciﬁcity of the amino terminal antibody deﬁnes if the immunometric assay measures only the bioactive PTH
circulating form (including the ﬁrst amino terminal amino acids) or the “intact” PTH, which includes, besides bioactive PTH,
other “long” carboxyl-terminal forms, for example, 7–84-PTH. Assays for “intact” PTH are the most commonly available and the
potential advantage of the bioactive PTH assays is still debatable. Next generation of assays will be based on diﬀerent principles,
mainly mass spectrometry in samples submitted to a prior puriﬁcation and fragmentation steps. These assays will provide
information about the whole spectra of PTH peptides in circulation, with a signiﬁcant increase of the information regarding
this biologically important peptide hormone.
1.Introduction
Parathyroid hormone (PTH) is a linear peptide consisting
of 84 amino acids and produced by the parathyroid cells.
It plays a critical role in the calcium metabolism, and its
receptor (PTH1R) is present in several tissues, with special
importance in renal tubules and bone cells. The classical
biological activity of PTH, mediated by PTHR1 activation,
is dependent on the presence of an intact amino terminal
sequence, mainly the ﬁrst amino acids. Yet PTH present in
circulation is very heterogeneous, and this heterogeneity is
the consequence of a complex metabolism that starts in the
parathyroidcellsandcontinuesinothertissues,mainlyinthe
kidneys and liver [1, 2]. The result of this complex metabo-
lism is the presence of a circulation pool of “PTH peptides,”
not only in pathological conditions, but also in normal
individuals. This phenomenon is particularly important in
patients with end-stage renal disease, where PTH fragments,
with marked predominance of the carboxyl terminal ones,
are present in great quantities in comparison to the intact
1–84 form (Figure 1)[ 3]. One important point is the fact
that the biologically active forms have very short half-lives,
compared to the carboxyl terminal fragments (devoid of the
amino terminal amino acids) that have longer half-lives and
accumulate in circulation as glomerular ﬁltration declines.
The recent demonstration of functional carboxyl-termi-
nal receptors for PTH, and of their potential physiological
importance, brought a new challenge in the interpretation of
PTH results [4–6]. The correct deﬁnition of the form recog-
nized by the assay employed for serum PTH measurement
becomes very important.
PTH measurement has evolved alongside immunoassay
methods for almost 50 years, since the ﬁrst practical method
was published in 1963 [7] .I ti sal o n gs t o r y ,a n dt h ea c -
cumulated knowledge about physiology and metabolism of
the molecule provided new tools for the development of new
assays in a continuous feedback process.
2. Evolutionof PTH Assays
We can divide, for the sake of simplicity, the evolution of
PTH assays in three groups of methods: the competitive2 Journal of Osteoporosis
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Figure 1: Elution proﬁle of a serum sample from a patient with end-stage renal disease loaded on a Hiload Superdex 30 1.6 × 60 column.
PTH was measured using a carboxyl terminal assay (“long” COOH) and a routine “intact” PTH assay.
immunoassays (1st generation), the immunometric assays
(2nd generation), and the new assays recently described
using mass spectrometry (3rd generation). In the ﬁrst case
a single polyclonal antibody competes for labeled PTH and
the serum forms. In the 2nd-generation assays, two distinct
antibodies (usually monoclonal), directed against diﬀerent
epitopes, bind the PTH forms present in the sample. One
of the antibodies is bound to a solid phase, and the other
is labeled. In the third type of assays, the recognition is based
on other principles (mass spectrometry) in serum samples
previously puriﬁed.
The ﬁrst description of a radioimmunoassay for PTH, by
Berson et al. in 1963 [7] was a tremendous breakthrough
and initiated a revolution in the diagnosis of parathyroid
conditions.Severalotherradioimmunoassaysweredescribed
in sequence, all based on antibodies raised against PTH
extracted form bovine or porcine parathyroid glands. These
heterogeneous 1st-generation assays had important limita-
tions, including the diﬃculty of producing antibodies with
suﬃcient aﬃnity and deﬁned speciﬁcity. These diﬃculties
derived from the fact that bioactive PTH circulates in con-
centrations that in normal individuals are below 10pmol/L,
which is per se a methodology challenge. The speciﬁcity of
these ﬁrst antibodies was directed mainly against carboxyl
fragments, the PTH form predominant in the gland extracts
used for immunization, for standard preparation and for
labeling. Nevertheless, immunoassays with reasonable char-
acteristics and clinical correlation were described [8, 9].
These carboxyl terminal assays had a major limitation that
was related to the retention of these fragments with decrease
in glomerular ﬁltration, rendering their use in chronic renal
disease patients almost invalid [10, 11].
With the description, by Potts et al. [12], that a synthetic
peptide comprising the 1–34 sequence of PTH was biologi-
cally active and equipotent to the complete 1–84 peptide, an
eﬀort to develop amino-terminal-speciﬁc assays ensued. The
ﬁrst such assay was published by Desplan et al. in 1977 [13],
followed by other publications [14, 15] .W eh a da ne x t e n s i v e
experience with the development and use of an amino-
terminal-speciﬁc radioimmunoassay for PTH. The assay was
based on egg-yolk-extracted antibodies, and despite prob-
lems in sensitivity, the assay was diagnostically superior to
themostavailablecarboxylterminalradioimmunoassay[16–
18].
3. Immunometric Assays:A New Benchmark
The description of the ﬁrst immunometric assay for PTH
(noncompetitive, “sandwich” type assay) by Nussbaum et al.
in 1987 [19] was a major breakthrough, and the sensi-
tivity and speciﬁcity problems were considered overcome.
Immunometric assays (2nd generation) are based on the
recognition of PTHbytwodiﬀerentantibodies, one carboxyl
terminalandtheotheraminoterminalspeciﬁc.Initiallythese
assays were considered to recognize only intact PTH (1–84)
and considered to be the gold standard for the deﬁnition
of parathyroid dysfunctions [20]. Nevertheless, publications
by the group of D’Amour et al. showed that it could not
be exactly the case [21, 22]. These authors showed that
PTH forms with deletion of the ﬁrst amino terminal amino
acids (mainly 7–84) are present in signiﬁcant concentration,
particular in patients with renal insuﬃciency. We conﬁrmed
these observation using an in-house immunoﬂuorometric
assay and HPLC separation for the PTH forms in circulation
[23]. Since the biological activity of PTH, via PTHR1 bind-
ing, depends on the presence of these ﬁrst amino acids, these
7–84formshavenoclassicalPTHbiologicalactivity.Therea-
sonwhythe“intact”assaysmeasuredalsothesedeletedforms
relatestothespeciﬁcityoftheaminoterminalantibodyused,
since most of them are directed to an antigenic site located
around amino acids 20 to 25 (amino terminal antibody
type 1 in Figure 2). This region of the molecule is moreJournal of Osteoporosis 3
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Figure 2: Schematic presentation of the regions of the PTH molecule recognized by the antibodies used in the immunometric assay design.
Amino terminal antibody type 1 represents the most common antibodies employed for amino terminal sequence recognition. Amino
terminal antibody type 2 refers to antibodies directed to the ﬁrst amino acids of PTH molecule.
antigenic, and a successful immunization (mice or other an-
imal) usually produces antibodies with that speciﬁcity. In
ordertohaveanassayrecognizingonlythebiologicallyactive
1–84 PTH form, the amino terminal antibody used should
recognize the ﬁrst amino acids (amino terminal antibody
type 2 in Figure 2). Assays with this speciﬁcity were de-
scribed, are available commercially, and were extensively
studied against the standard immunometric assays [24, 25].
The conclusion of all these studies was that besides having
a lower reference range, these “biologically active” 1–84 PTH
assaysshowednoclearadvantageoverthemoreavailable,less
expensive, and extensively validated “intact” assays [26].
4. CurrentState
Immunometric assays for measurement of “intact” serum
PTH are widely available in clinical laboratories, have good
sensitivity and reproducibility, and well-deﬁned normal
reference values [27, 28]. One point is still debatable and
relates to the use of these assays in patients with hyper-
parathyroidism secondary to renal insuﬃciency, since as
described by Quarles et al. in 1994, dissociation between
serum PTH levels and bone abnormality exists in these pa-
tients [29]. One logical solution, the use of the immuno-
metric assays that measures only the “biologically active” 1–
84 PTH form, showed no diagnostic advantage [30]. The
conclusion is that some form of skeletal resistance exists
in this condition, and it may be in part explained by the
interaction of PTH molecules that bind to PTHR1 but do
not activate it. These somewhat unexpected observations
may be related to the notion that PTH should be viewed as
a polyhormone, a concept ﬁrst raised by Mallette in 1991
[31]. The wide range of circulating forms of PTH may
include forms with biological activity diﬀerent from those
expected by the activation of PTHR1 [3–6]. This observation
can be further stressed by the recent description, in some
parathyroid carcinoma patients, of circulating forms of PTH
that are able to activate PTHR1 but are not recognized by the
current “intact” assays [32].
5.FutureProspects
The additional information potentially provided by the
measurement of the various forms of circulating PTH pep-
tides is very attractive, but attaining this goal using immuno-
metric assays would require several diﬀerent assays. The use
of liquid chromatography coupled to tandem mass spec-
trometry in the clinical laboratory is rapidly maturing and
is already in routine in diagnostic laboratories for steroid
hormones [33]. The enormous potential of these techniques
already led to the development of methods that associate
immunoaﬃnity, in situ digestion, and mass spectrometry
for the discrimination and quantiﬁcation of the pool of
circulating PTH forms [34, 35]. We foresee these techniques
(3rd generation) as the next step in PTH quantiﬁcation, with
broad new clinical applications.4 Journal of Osteoporosis
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